目的观察芪参还五胶囊对冠心病患者心功能的改善及对外周血Th17/Treg平衡的影响。方法选择于医院治疗的110例冠心病患者,2021年1月—2022年6月为病例入组时间,分组方式为随机数字表法,西医组55例,给予西医基础治疗;芪参还五胶囊组55例,...目的观察芪参还五胶囊对冠心病患者心功能的改善及对外周血Th17/Treg平衡的影响。方法选择于医院治疗的110例冠心病患者,2021年1月—2022年6月为病例入组时间,分组方式为随机数字表法,西医组55例,给予西医基础治疗;芪参还五胶囊组55例,在西医基础治疗同时给予患者芪参还五胶囊治疗。治疗前、后检测两组患者Th17/Treg细胞比例、血红素加氧酶1(HO-1)、一氧化氮(NO)、白细胞介素-35(IL-35)、脂联素(APN)、白细胞介素-17A(IL-17A)、血管性血友病因子(vWF)、脂蛋白相关磷脂酶A2(Lp-PLA2)水平,检测患者冠状动脉微循环指标:冠状动脉血流储备(CFR)、血流量(Qmean)、平均循环抵抗指数(IMR),检测患者心肌耗氧量、左室射血分数(LVEF)、连续窦性R-R间期标准差(SDNN)、24 h QT离散度(QTd),给予患者动则喘息、胸闷气短、心胸隐痛、胸痛反复发作、倦怠懒言、面色㿠白评价,比较西医组及芪参还五胶囊组临床疗效。结果芪参还五胶囊组患者Th17/Treg、IL-17A含量较西医组明显降低(P<0.05),芪参还五胶囊组HO-1、IL-35含量较西医组升高(P<0.005);芪参还五胶囊组患者Lp-PLA2、vWF含量较西医组明显降低(P<0.05),芪参还五胶囊组患者NO、APN含量较西医组升高(P<0.05);芪参还五胶囊组CFR、Qmean较西医组明显升高(P<0.05),芪参还五胶囊组IMR较西医组明显降低(P<0.05);芪参还五胶囊组患者心肌耗氧量、QTd较西医组明显降低(P<0.05),芪参还五胶囊组LVEF、SDNN较西医组升高(P<0.05);芪参还五胶囊组患者心悸易汗、动则喘息、胸闷气短、心胸隐痛、胸痛反复发作、倦怠懒言、面色㿠白评分较西医组明显降低(P<0.05),芪参还五胶囊组总有效率为98.18%,西医组总有效率为83.64%,芪参还五胶囊组患者总有效率高于西医组(P<0.05)。结论芪参还五胶囊治疗冠心病患者,可调节机体Th17/Treg平衡,抑制机体炎症,减少血管内皮损伤,改善患者心功能、冠状动脉微循环及心电图指标,提升患者临床疗效。展开更多
The interleukin-17 family is the key group of cytokines and displays a broad spectrum of biological functions,including regulating the inflammatory cascade in various autoimmune and inflammatory diseases,such as multi...The interleukin-17 family is the key group of cytokines and displays a broad spectrum of biological functions,including regulating the inflammatory cascade in various autoimmune and inflammatory diseases,such as multiple sclerosis,neuromyelitis optica spectrum disorder,myasthenia gravis,Guillain–Barre syndrome,acute disseminated encephalomyelitis,diabetes,inflammatory skin diseases,joint inflammation,and cancer.Although the function of the interleukin-17 family has attracted increasing research attention over many years,the expression,function,and regulation mechanisms of different interleukin-17 members are complicated and still only partially understood.Currently,the interleukin-17A pathway is considered a critical therapeutic target for numerous immune and chronic inflammatory diseases,with several monoclonal antibodies against interleukin-17A having been successfully used in clinical practice.Whether other interleukin-17 members have the potential to be targeted in other diseases is still debated.This review first summarizes the recent advancements in understanding the physicochemical properties,physiological functions,cellular origins,and downstream signaling pathways of different members and corresponding receptors of the interleukin-17 family.Subsequently,the function of interleukin-17 in various immune diseases is discussed,and the important role of interleukin-17 in the pathological process of immune diseases is demonstrated from multiple perspectives.Then,the current status of targeted interleukin-17 therapy is summarized,and the effectiveness and safety of targeted interleukin-17 therapy are analyzed.Finally,the clinical application prospects of targeting the interleukin-17 pathway are discussed.展开更多
AIM:To investigate the genetic basis of Weill-Marchesani syndrome(WMS)in a Chinese family and clarify the pathogenic mechanism of novel ADAMTS17 mutations.METHODS:Comprehensive clinical assessments and genetic analyse...AIM:To investigate the genetic basis of Weill-Marchesani syndrome(WMS)in a Chinese family and clarify the pathogenic mechanism of novel ADAMTS17 mutations.METHODS:Comprehensive clinical assessments and genetic analyses were performed on a Chinese family with two affected siblings.Whole-exome sequencing(WES)was conducted for the proband and other family members.Bioinformatics tools were used to evaluate the conservation,predicted pathogenicity,and structural effects of the identified ADAMTS17 variants.In addition,protein structure modeling was applied to assess the functional impacts of the mutations.RESULTS:The proband(a 32-year-old male)and his elder sister(42y)presented typical clinical features of WMS,including short stature,brachydactyly,high myopia,ectopia lentis,and secondary glaucoma.WES identified a novel compound heterozygous mutation in ADAMTS17:a splicing mutation(c.451-2A>G)inherited from the father and a missense mutation(c.1043G>A;p.C348Y)inherited from the mother.The splicing mutation disrupted normal mRNA splicing and processing,leading to premature translation termination.The missense mutation,which is located in the metalloprotease catalytic domain,was predicted to abolish a critical disulfide bond,thereby impairing protein stability.Both mutations exhibited high evolutionary conservation and were predicted to be pathogenic by multiple bioinformatics algorithms.CONCLUSION:A novel compound heterozygous mutation in ADAMTS17 is identified in this WMS-affected Chinese family,and its pathogenicity is verified via bioinformatics analysis and protein structural modeling.These findings are expected to facilitate the genetic diagnosis of WMS and deepen the understanding of its molecular pathogenesis.展开更多
目的探讨银杏内酯B通过激活免疫性血小板减少症(ITP)哺乳动物雷帕霉素靶蛋白(mTOR)信号通路调节长链非编码RNA人浆细胞瘤转化迁移基因1(lncRNA PVT1)促进调节性T淋巴细胞/辅助性T淋巴细胞17(Treg/Th17)免疫平衡而抑制炎症反应的机制。...目的探讨银杏内酯B通过激活免疫性血小板减少症(ITP)哺乳动物雷帕霉素靶蛋白(mTOR)信号通路调节长链非编码RNA人浆细胞瘤转化迁移基因1(lncRNA PVT1)促进调节性T淋巴细胞/辅助性T淋巴细胞17(Treg/Th17)免疫平衡而抑制炎症反应的机制。方法选用80只雄性SD小鼠,采用腹腔注射抗小鼠血小板血清方法建立模型,随机分为正常组、模型组、低剂量组、高剂量组,每组20只,连续给药14天。实时荧光定量PCR(qRT-PCR)检测血清lncRNA PVT1表达,流式细胞仪检测Treg/Th17细胞,Western Blot检测磷脂酰肌醇-3-激酶(PI3K)、Akt、mTOR蛋白表达。检测血清白细胞介素-4(IL-4)、干扰素-γ(IFN-γ)和全血血小板计数(PLT)。结果与正常组比较,模型组小鼠血清lncRNA PVT1、Th17、IFN-γ升高,Treg、Treg/Th17、PI3K、Akt、mTOR蛋白、IL-4、PLT降低,差异具有统计学意义(t=2.510~54.899,均P<0.05);与模型组比较,低剂量组、高剂量组lncRNA PVT1(1.99±0.14、1.25±0.11 vs 2.39±0.15)、Th17(1.76%±0.32%、0.87%±0.04%vs 5.28%±1.21%)、IFN-γ(7.65±0.28pg/ml、6.84±0.33pg/ml vs 8.45±0.36 pg/ml)均降低(t_(低剂量组)=8.718、8.782、3.292,t_(高剂量组)=27.408、9.789、6.542),Treg(3.46%±0.43%、4.77%±0.51%vs 2.41%±0.44%)、Treg/Th17(1.98±0.16、4.24±1.02 vs 0.45±0.05)、PI3K(0.88±0.08、1.22±0.21 vs 0.45±0.05)、Akt(0.66±0.07、1.11±0.11 vs 0.21±0.02)、mTOR蛋白(0.70±0.08、1.21±0.13 vs 0.45±0.06)、IL-4(12.28±1.28pg/ml、13.08±1.01pg/ml vs 11.45±1.05pg/ml)、PLT[(526.99±50.34)×10^(9)/L、(880.37±52.78)×10^(9)/L vs(218.58±50.35)×10^(9)/L]均升高(t_(低剂量组)=4.943~27.643,t_(高剂量组)=7.766~40.818),差异具有统计学意义(均P<0.05)。与低剂量组比较,高剂量组lncRNA PVT1、Th17、IFN-γ降低,Treg、Treg/Th17、PI3K、Akt、mTOR蛋白、IL-4、PLT升高,差异具有统计学意义(t=2.411~21.667,均P<0.05)。结论银杏内酯B可通过激活mTOR信号通路,调节lncRNA PVT1促进Treg/Th17免疫平衡,抑制ITP小鼠炎症反应,提升血小板数量。展开更多
Background:ZhiZi-BoPi Decoction(ZZBPD),a traditional prescription for liver and gallbladder protection,has garnered significant clinical interest due to its hepatoprotective properties.Despite its proven efficacy in m...Background:ZhiZi-BoPi Decoction(ZZBPD),a traditional prescription for liver and gallbladder protection,has garnered significant clinical interest due to its hepatoprotective properties.Despite its proven efficacy in mitigating intrahepatic cholestasis,the precise mechanisms underlying its therapeutic effects remain inadequately understood.This study aims to comprehensively investigate the pharmacological mechanisms underlying the therapeutic effects of ZZBPD in cholestatic liver injury(CLI).Methods:Firstly,we evaluated the hepatoprotective effects of ZZBPD on mice with CLI induced byα-naphthylisothiocyanate(ANIT),by measuring biochemical markers,inflammatory factors,and bile acid levels.Subsequently,we employed network pharmacology and single-cell RNA sequencing(scRNA-seq)to identify key targets and potential signaling pathways for the prevention and treatment of CLI.Finally,we further validated the mechanism of action of ZZBPD on these key targets through molecular docking,western blotting,and immunofluorescence techniques.Results:ZZBPD notably improved serum liver function,reduced hepatic inflammation,and restored bile acid balance.Through network pharmacology and scRNA-seq analysis,48 core targets were identified,including TNF,IL-6,and NFKB1,all of which are linked to the IL-17 and NF-κB signaling pathways,as shown by KEGG enrichment analysis.Molecular docking further confirmed stable interactions between ZZBPD’s key active components and molecules such as IL-6,IL-17,and NF-κB.Additionally,western blotting and immunofluorescence validated the downregulation of IL-17 and NF-κB protein expression in liver tissue.Conclusion:ZZBPD effectively treats CLI by activating pathways related to the bile acid receptor FXR,while also modulating the IL-17/NF-κB signaling pathway.This dual action enhances bile secretion and alleviates liver inflammation.These findings offer important insights into the pharmacological mechanisms of ZZBPD and underscore its potential as a promising therapeutic for CLI.展开更多
文摘目的观察芪参还五胶囊对冠心病患者心功能的改善及对外周血Th17/Treg平衡的影响。方法选择于医院治疗的110例冠心病患者,2021年1月—2022年6月为病例入组时间,分组方式为随机数字表法,西医组55例,给予西医基础治疗;芪参还五胶囊组55例,在西医基础治疗同时给予患者芪参还五胶囊治疗。治疗前、后检测两组患者Th17/Treg细胞比例、血红素加氧酶1(HO-1)、一氧化氮(NO)、白细胞介素-35(IL-35)、脂联素(APN)、白细胞介素-17A(IL-17A)、血管性血友病因子(vWF)、脂蛋白相关磷脂酶A2(Lp-PLA2)水平,检测患者冠状动脉微循环指标:冠状动脉血流储备(CFR)、血流量(Qmean)、平均循环抵抗指数(IMR),检测患者心肌耗氧量、左室射血分数(LVEF)、连续窦性R-R间期标准差(SDNN)、24 h QT离散度(QTd),给予患者动则喘息、胸闷气短、心胸隐痛、胸痛反复发作、倦怠懒言、面色㿠白评价,比较西医组及芪参还五胶囊组临床疗效。结果芪参还五胶囊组患者Th17/Treg、IL-17A含量较西医组明显降低(P<0.05),芪参还五胶囊组HO-1、IL-35含量较西医组升高(P<0.005);芪参还五胶囊组患者Lp-PLA2、vWF含量较西医组明显降低(P<0.05),芪参还五胶囊组患者NO、APN含量较西医组升高(P<0.05);芪参还五胶囊组CFR、Qmean较西医组明显升高(P<0.05),芪参还五胶囊组IMR较西医组明显降低(P<0.05);芪参还五胶囊组患者心肌耗氧量、QTd较西医组明显降低(P<0.05),芪参还五胶囊组LVEF、SDNN较西医组升高(P<0.05);芪参还五胶囊组患者心悸易汗、动则喘息、胸闷气短、心胸隐痛、胸痛反复发作、倦怠懒言、面色㿠白评分较西医组明显降低(P<0.05),芪参还五胶囊组总有效率为98.18%,西医组总有效率为83.64%,芪参还五胶囊组患者总有效率高于西医组(P<0.05)。结论芪参还五胶囊治疗冠心病患者,可调节机体Th17/Treg平衡,抑制机体炎症,减少血管内皮损伤,改善患者心功能、冠状动脉微循环及心电图指标,提升患者临床疗效。
基金supported by the National Natural Science Foundational of China(Key Program),No.U24A20692(to CJZ)the National Natural Science Foundational of China,Nos.82101414(to MLJ),82371355(to CJZ)+4 种基金the National Natural Science Foundational of China for Excellent Young Scholars,No.82022019(to CJZ)Sichuan Special Fund for Distinguished Young Scholars,No.24NSFJQ0052(to CJZ)The Innovation and Entrepreneurial Team of Sichuan Tianfu Emei Program,No.CZ2024018(to CJZ)Funding for Distinguished Young Scholars of Sichuan Provincial People’s Hospital,No.30420230005(to CJZ)Funding for Distinguished Young Scholars of University of Electronic Science and Technology of China,No.A1098531023601381(to CJZ)。
文摘The interleukin-17 family is the key group of cytokines and displays a broad spectrum of biological functions,including regulating the inflammatory cascade in various autoimmune and inflammatory diseases,such as multiple sclerosis,neuromyelitis optica spectrum disorder,myasthenia gravis,Guillain–Barre syndrome,acute disseminated encephalomyelitis,diabetes,inflammatory skin diseases,joint inflammation,and cancer.Although the function of the interleukin-17 family has attracted increasing research attention over many years,the expression,function,and regulation mechanisms of different interleukin-17 members are complicated and still only partially understood.Currently,the interleukin-17A pathway is considered a critical therapeutic target for numerous immune and chronic inflammatory diseases,with several monoclonal antibodies against interleukin-17A having been successfully used in clinical practice.Whether other interleukin-17 members have the potential to be targeted in other diseases is still debated.This review first summarizes the recent advancements in understanding the physicochemical properties,physiological functions,cellular origins,and downstream signaling pathways of different members and corresponding receptors of the interleukin-17 family.Subsequently,the function of interleukin-17 in various immune diseases is discussed,and the important role of interleukin-17 in the pathological process of immune diseases is demonstrated from multiple perspectives.Then,the current status of targeted interleukin-17 therapy is summarized,and the effectiveness and safety of targeted interleukin-17 therapy are analyzed.Finally,the clinical application prospects of targeting the interleukin-17 pathway are discussed.
文摘AIM:To investigate the genetic basis of Weill-Marchesani syndrome(WMS)in a Chinese family and clarify the pathogenic mechanism of novel ADAMTS17 mutations.METHODS:Comprehensive clinical assessments and genetic analyses were performed on a Chinese family with two affected siblings.Whole-exome sequencing(WES)was conducted for the proband and other family members.Bioinformatics tools were used to evaluate the conservation,predicted pathogenicity,and structural effects of the identified ADAMTS17 variants.In addition,protein structure modeling was applied to assess the functional impacts of the mutations.RESULTS:The proband(a 32-year-old male)and his elder sister(42y)presented typical clinical features of WMS,including short stature,brachydactyly,high myopia,ectopia lentis,and secondary glaucoma.WES identified a novel compound heterozygous mutation in ADAMTS17:a splicing mutation(c.451-2A>G)inherited from the father and a missense mutation(c.1043G>A;p.C348Y)inherited from the mother.The splicing mutation disrupted normal mRNA splicing and processing,leading to premature translation termination.The missense mutation,which is located in the metalloprotease catalytic domain,was predicted to abolish a critical disulfide bond,thereby impairing protein stability.Both mutations exhibited high evolutionary conservation and were predicted to be pathogenic by multiple bioinformatics algorithms.CONCLUSION:A novel compound heterozygous mutation in ADAMTS17 is identified in this WMS-affected Chinese family,and its pathogenicity is verified via bioinformatics analysis and protein structural modeling.These findings are expected to facilitate the genetic diagnosis of WMS and deepen the understanding of its molecular pathogenesis.
文摘目的探讨银杏内酯B通过激活免疫性血小板减少症(ITP)哺乳动物雷帕霉素靶蛋白(mTOR)信号通路调节长链非编码RNA人浆细胞瘤转化迁移基因1(lncRNA PVT1)促进调节性T淋巴细胞/辅助性T淋巴细胞17(Treg/Th17)免疫平衡而抑制炎症反应的机制。方法选用80只雄性SD小鼠,采用腹腔注射抗小鼠血小板血清方法建立模型,随机分为正常组、模型组、低剂量组、高剂量组,每组20只,连续给药14天。实时荧光定量PCR(qRT-PCR)检测血清lncRNA PVT1表达,流式细胞仪检测Treg/Th17细胞,Western Blot检测磷脂酰肌醇-3-激酶(PI3K)、Akt、mTOR蛋白表达。检测血清白细胞介素-4(IL-4)、干扰素-γ(IFN-γ)和全血血小板计数(PLT)。结果与正常组比较,模型组小鼠血清lncRNA PVT1、Th17、IFN-γ升高,Treg、Treg/Th17、PI3K、Akt、mTOR蛋白、IL-4、PLT降低,差异具有统计学意义(t=2.510~54.899,均P<0.05);与模型组比较,低剂量组、高剂量组lncRNA PVT1(1.99±0.14、1.25±0.11 vs 2.39±0.15)、Th17(1.76%±0.32%、0.87%±0.04%vs 5.28%±1.21%)、IFN-γ(7.65±0.28pg/ml、6.84±0.33pg/ml vs 8.45±0.36 pg/ml)均降低(t_(低剂量组)=8.718、8.782、3.292,t_(高剂量组)=27.408、9.789、6.542),Treg(3.46%±0.43%、4.77%±0.51%vs 2.41%±0.44%)、Treg/Th17(1.98±0.16、4.24±1.02 vs 0.45±0.05)、PI3K(0.88±0.08、1.22±0.21 vs 0.45±0.05)、Akt(0.66±0.07、1.11±0.11 vs 0.21±0.02)、mTOR蛋白(0.70±0.08、1.21±0.13 vs 0.45±0.06)、IL-4(12.28±1.28pg/ml、13.08±1.01pg/ml vs 11.45±1.05pg/ml)、PLT[(526.99±50.34)×10^(9)/L、(880.37±52.78)×10^(9)/L vs(218.58±50.35)×10^(9)/L]均升高(t_(低剂量组)=4.943~27.643,t_(高剂量组)=7.766~40.818),差异具有统计学意义(均P<0.05)。与低剂量组比较,高剂量组lncRNA PVT1、Th17、IFN-γ降低,Treg、Treg/Th17、PI3K、Akt、mTOR蛋白、IL-4、PLT升高,差异具有统计学意义(t=2.411~21.667,均P<0.05)。结论银杏内酯B可通过激活mTOR信号通路,调节lncRNA PVT1促进Treg/Th17免疫平衡,抑制ITP小鼠炎症反应,提升血小板数量。
基金supported by the National Science Foundation of China(No.82405004,82474253)the Natural Science Foundation postdoctoral project of Chongqing(CSTB2022NSCQ-BHX0709)+2 种基金Chongqing Wanzhou District doctoral“through train”scientific research project(wzstc-20220124)Natural Science Foundation of Chongqing,China(No.Cstc2021jcyj-msxmX0996)Chongqing Wanzhou District Science and Health Joint Medical Research Project(wzstc-kw2023032)。
文摘Background:ZhiZi-BoPi Decoction(ZZBPD),a traditional prescription for liver and gallbladder protection,has garnered significant clinical interest due to its hepatoprotective properties.Despite its proven efficacy in mitigating intrahepatic cholestasis,the precise mechanisms underlying its therapeutic effects remain inadequately understood.This study aims to comprehensively investigate the pharmacological mechanisms underlying the therapeutic effects of ZZBPD in cholestatic liver injury(CLI).Methods:Firstly,we evaluated the hepatoprotective effects of ZZBPD on mice with CLI induced byα-naphthylisothiocyanate(ANIT),by measuring biochemical markers,inflammatory factors,and bile acid levels.Subsequently,we employed network pharmacology and single-cell RNA sequencing(scRNA-seq)to identify key targets and potential signaling pathways for the prevention and treatment of CLI.Finally,we further validated the mechanism of action of ZZBPD on these key targets through molecular docking,western blotting,and immunofluorescence techniques.Results:ZZBPD notably improved serum liver function,reduced hepatic inflammation,and restored bile acid balance.Through network pharmacology and scRNA-seq analysis,48 core targets were identified,including TNF,IL-6,and NFKB1,all of which are linked to the IL-17 and NF-κB signaling pathways,as shown by KEGG enrichment analysis.Molecular docking further confirmed stable interactions between ZZBPD’s key active components and molecules such as IL-6,IL-17,and NF-κB.Additionally,western blotting and immunofluorescence validated the downregulation of IL-17 and NF-κB protein expression in liver tissue.Conclusion:ZZBPD effectively treats CLI by activating pathways related to the bile acid receptor FXR,while also modulating the IL-17/NF-κB signaling pathway.This dual action enhances bile secretion and alleviates liver inflammation.These findings offer important insights into the pharmacological mechanisms of ZZBPD and underscore its potential as a promising therapeutic for CLI.
